N-acetylcysteine in severe falciparum malaria in Thailand

Sombat Treeprasertsuk, Srivicha Krudsood, Thanawat Tosukhowong, Wirach Maek-A-Nantawat, Suparp Vannaphan, Tosaporn Saengnetswang, Sornchai Looareesuwan, Walter F Kuhn, Gary Brittenham, James Edwin Carroll

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

One hundred and eight patients with severe falciparum malaria underwent a placebo controlled trial with the antioxidant, N-acetylcysteine (NAC), as an adjunctive therapy along with standard intravenous artesunate therapy. Three NAC dosage regimens were used: an intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours intravenously for up to 18 doses (Group 1); a single intravenous loading dose followed by oral NAC in the same amount as for Group 1 (Group 2); a regimen identical to Group 1 except that oral NAC was administered after the first 24 hours (Group 3). Fifty-four patients received placebo plus artesunate. Two critically ill patients died in Group 1. No patient sustained an adverse reaction to the NAC other than vomiting, and the deaths were attributed to severe disease with multiple organ involvement. The excellent results with NAC, the lack of adverse effects, and the rationale for NAC benefit supports the need for a large, double blind trial of NAC as an adjunctive therapy for severe malaria.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalSoutheast Asian Journal of Tropical Medicine and Public Health
Volume34
Issue number1
StatePublished - Mar 1 2003

Fingerprint

Falciparum Malaria
Acetylcysteine
Thailand
Placebos
Critical Illness
Malaria
Vomiting
Therapeutics
Antioxidants

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Treeprasertsuk, S., Krudsood, S., Tosukhowong, T., Maek-A-Nantawat, W., Vannaphan, S., Saengnetswang, T., ... Carroll, J. E. (2003). N-acetylcysteine in severe falciparum malaria in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health, 34(1), 37-42.

N-acetylcysteine in severe falciparum malaria in Thailand. / Treeprasertsuk, Sombat; Krudsood, Srivicha; Tosukhowong, Thanawat; Maek-A-Nantawat, Wirach; Vannaphan, Suparp; Saengnetswang, Tosaporn; Looareesuwan, Sornchai; Kuhn, Walter F; Brittenham, Gary; Carroll, James Edwin.

In: Southeast Asian Journal of Tropical Medicine and Public Health, Vol. 34, No. 1, 01.03.2003, p. 37-42.

Research output: Contribution to journalArticle

Treeprasertsuk, S, Krudsood, S, Tosukhowong, T, Maek-A-Nantawat, W, Vannaphan, S, Saengnetswang, T, Looareesuwan, S, Kuhn, WF, Brittenham, G & Carroll, JE 2003, 'N-acetylcysteine in severe falciparum malaria in Thailand', Southeast Asian Journal of Tropical Medicine and Public Health, vol. 34, no. 1, pp. 37-42.
Treeprasertsuk S, Krudsood S, Tosukhowong T, Maek-A-Nantawat W, Vannaphan S, Saengnetswang T et al. N-acetylcysteine in severe falciparum malaria in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health. 2003 Mar 1;34(1):37-42.
Treeprasertsuk, Sombat ; Krudsood, Srivicha ; Tosukhowong, Thanawat ; Maek-A-Nantawat, Wirach ; Vannaphan, Suparp ; Saengnetswang, Tosaporn ; Looareesuwan, Sornchai ; Kuhn, Walter F ; Brittenham, Gary ; Carroll, James Edwin. / N-acetylcysteine in severe falciparum malaria in Thailand. In: Southeast Asian Journal of Tropical Medicine and Public Health. 2003 ; Vol. 34, No. 1. pp. 37-42.
@article{98613e1cd8f142f4bca4555e4a93ea58,
title = "N-acetylcysteine in severe falciparum malaria in Thailand",
abstract = "One hundred and eight patients with severe falciparum malaria underwent a placebo controlled trial with the antioxidant, N-acetylcysteine (NAC), as an adjunctive therapy along with standard intravenous artesunate therapy. Three NAC dosage regimens were used: an intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours intravenously for up to 18 doses (Group 1); a single intravenous loading dose followed by oral NAC in the same amount as for Group 1 (Group 2); a regimen identical to Group 1 except that oral NAC was administered after the first 24 hours (Group 3). Fifty-four patients received placebo plus artesunate. Two critically ill patients died in Group 1. No patient sustained an adverse reaction to the NAC other than vomiting, and the deaths were attributed to severe disease with multiple organ involvement. The excellent results with NAC, the lack of adverse effects, and the rationale for NAC benefit supports the need for a large, double blind trial of NAC as an adjunctive therapy for severe malaria.",
author = "Sombat Treeprasertsuk and Srivicha Krudsood and Thanawat Tosukhowong and Wirach Maek-A-Nantawat and Suparp Vannaphan and Tosaporn Saengnetswang and Sornchai Looareesuwan and Kuhn, {Walter F} and Gary Brittenham and Carroll, {James Edwin}",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "34",
pages = "37--42",
journal = "Southeast Asian Journal of Tropical Medicine and Public Health",
issn = "0125-1562",
publisher = "Southeast Asian Ministers of Education Organisation",
number = "1",

}

TY - JOUR

T1 - N-acetylcysteine in severe falciparum malaria in Thailand

AU - Treeprasertsuk, Sombat

AU - Krudsood, Srivicha

AU - Tosukhowong, Thanawat

AU - Maek-A-Nantawat, Wirach

AU - Vannaphan, Suparp

AU - Saengnetswang, Tosaporn

AU - Looareesuwan, Sornchai

AU - Kuhn, Walter F

AU - Brittenham, Gary

AU - Carroll, James Edwin

PY - 2003/3/1

Y1 - 2003/3/1

N2 - One hundred and eight patients with severe falciparum malaria underwent a placebo controlled trial with the antioxidant, N-acetylcysteine (NAC), as an adjunctive therapy along with standard intravenous artesunate therapy. Three NAC dosage regimens were used: an intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours intravenously for up to 18 doses (Group 1); a single intravenous loading dose followed by oral NAC in the same amount as for Group 1 (Group 2); a regimen identical to Group 1 except that oral NAC was administered after the first 24 hours (Group 3). Fifty-four patients received placebo plus artesunate. Two critically ill patients died in Group 1. No patient sustained an adverse reaction to the NAC other than vomiting, and the deaths were attributed to severe disease with multiple organ involvement. The excellent results with NAC, the lack of adverse effects, and the rationale for NAC benefit supports the need for a large, double blind trial of NAC as an adjunctive therapy for severe malaria.

AB - One hundred and eight patients with severe falciparum malaria underwent a placebo controlled trial with the antioxidant, N-acetylcysteine (NAC), as an adjunctive therapy along with standard intravenous artesunate therapy. Three NAC dosage regimens were used: an intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours intravenously for up to 18 doses (Group 1); a single intravenous loading dose followed by oral NAC in the same amount as for Group 1 (Group 2); a regimen identical to Group 1 except that oral NAC was administered after the first 24 hours (Group 3). Fifty-four patients received placebo plus artesunate. Two critically ill patients died in Group 1. No patient sustained an adverse reaction to the NAC other than vomiting, and the deaths were attributed to severe disease with multiple organ involvement. The excellent results with NAC, the lack of adverse effects, and the rationale for NAC benefit supports the need for a large, double blind trial of NAC as an adjunctive therapy for severe malaria.

UR - http://www.scopus.com/inward/record.url?scp=0042066708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042066708&partnerID=8YFLogxK

M3 - Article

C2 - 12971512

AN - SCOPUS:0042066708

VL - 34

SP - 37

EP - 42

JO - Southeast Asian Journal of Tropical Medicine and Public Health

JF - Southeast Asian Journal of Tropical Medicine and Public Health

SN - 0125-1562

IS - 1

ER -